In this review, the main clinical manifestations of calcium pyrophosphate dihydrate and basic calcium phosphate crystal deposition are discussed, along with the biological effects of these crystals, current therapeutic approaches and future directions in therapy [ read more ]. McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

Telitacicept consists of the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) receptor fused to the Fc domain of human IgG1, and the recombinant protein was designed to inhibit B-lymphocyte stimulator and the APRIL proliferation-inducing ligand. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ACR Convergence 2022; Philadelphia, Pennsylvania, USA: November 10–14

Withdrawing therapy on the basis of low levels of high-sensitivity C-reactive protein and the calcium-binding protein S100A12 may be a feasible approach for young people with juvenile idiopathic arthritis in remission, PREVENT-JIA study data show.

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

In rheumatic diseases it is widely used for the treatment of gout, calcium pyrophosphate deposition disease, and familial Mediterranean fever.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

How will the FAST trial results impact regulatory guidance & clinical practice?

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

All participants also received calcium 1000 mg/day and vitamin D 800 IU/day supplementation.

Given that the summary of product characteristics advises estimation of calcium concentration every time prior to administration of denosumab (to identify patients at risk for hypocalcemia), it is possible that cases of transient mild hypercalcemia will be identified with unnecessary concern and unwarranted investigations.